Market Leadership As a joint venture between Novartis and GSK, the company holds a strong market position as a leader in over 30 countries and the top global OTC medicines provider, offering a compelling case for expanding regional and product-based sales efforts.

Strategic Acquisitions Recent acquisitions of assets like Excellergy and Azstarys, along with substantial investments in breast cancer drug candidates, suggest active portfolio expansion, opening opportunities to cross-sell complementary therapies or target new patient segments.

US Expansion Planned U.S. facility expansions backed by a $23 billion investment highlight a focus on increasing production capacity and market engagement in North America, presenting potential for sales of manufacturing and supply chain solutions.

Innovation Focus Investments in cutting-edge therapies such as trifunctional effector cell inhibitors and mutant-selective inhibitors indicate a strong emphasis on innovative treatments, creating opportunities to partner on advanced research tools, technologies, and clinical support services.

Legal and Ethical Outreach Recent legal issues surrounding data privacy suggest a need for enhanced compliance and cybersecurity solutions, presenting a potential avenue for sales of data management and legal consultancy services to reinforce regulatory adherence.